These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 3961504)

  • 21. Warfarin. From bedside to bench.
    Wessler S; Gitel SN
    N Engl J Med; 1984 Sep; 311(10):645-52. PubMed ID: 6472343
    [No Abstract]   [Full Text] [Related]  

  • 22. The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: clinical implications.
    Gitel SN; Wessler S
    J Lab Clin Med; 1979 Sep; 94(3):481-8. PubMed ID: 469382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guidelines on oral anticoagulation (warfarin): third edition--2005 update.
    Baglin TP; Keeling DM; Watson HG;
    Br J Haematol; 2006 Feb; 132(3):277-85. PubMed ID: 16409292
    [No Abstract]   [Full Text] [Related]  

  • 24. Coagulation assays.
    Bates SM; Weitz JI
    Circulation; 2005 Jul; 112(4):e53-60. PubMed ID: 16043649
    [No Abstract]   [Full Text] [Related]  

  • 25. [Heparins, antivitamins K. Principles and rules of use. Posology of non-fractionated heparins].
    Delsart D; Chambefort V; Decousus H
    Rev Prat; 2001 Sep; 51(13):1489-97. PubMed ID: 11601082
    [No Abstract]   [Full Text] [Related]  

  • 26. [Prescription and monitoring of anticoagulant therapies].
    Laviolle B; Oger E
    Rev Prat; 2008 Nov; 58(18):2063-70. PubMed ID: 19143281
    [No Abstract]   [Full Text] [Related]  

  • 27. The evolution of oral anticoagulant therapy.
    Dittus C; Ansell J
    Prim Care; 2013 Mar; 40(1):109-34. PubMed ID: 23402464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Influence of the protein induced by vitamin K absence on thrombotest and hepaplastintest in the patients treated with oral anticoagulant].
    Murakami S; Muratani H; Kikuchi T; Fujimoto S; Hayashi T; Inai S; Imaoka S
    Rinsho Byori; 1983 Jan; 31(1):105-9. PubMed ID: 6865023
    [No Abstract]   [Full Text] [Related]  

  • 29. Anticoagulation of juvenile sheep and goats with heparin, warfarin, and clopidogrel.
    Connell JM; Khalapyan T; Al-Mondhiry HA; Wilson RP; Rosenberg G; Weiss WJ
    ASAIO J; 2007; 53(2):229-37. PubMed ID: 17413565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comprehensive model for the humoral coagulation network in humans.
    Wajima T; Isbister GK; Duffull SB
    Clin Pharmacol Ther; 2009 Sep; 86(3):290-8. PubMed ID: 19516255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.
    Jackson CV; Crowe VG; Frank JD; Wilson HC; Coffman WJ; Utterback BG; Jakubowski JA; Smith GF
    J Pharmacol Exp Ther; 1992 May; 261(2):546-52. PubMed ID: 1578372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Variability of INR due to thromboplastin. Comparison of two recombinant thromboplastins and one rabbit thromboplastin].
    Renier JL; Baufine-Ducrocq H; Samama MM
    Ann Biol Clin (Paris); 1995; 53(6):353-6. PubMed ID: 8572381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Anticoagulants (heparin, antivitamins K, principles and rules of use)].
    Lecompte T; Horellou MH
    Rev Prat; 1992 May; 42(10):1280-8. PubMed ID: 1609224
    [No Abstract]   [Full Text] [Related]  

  • 34. Why warfarin and heparin need to overlap when treating acute venous thromboembolism.
    Wittkowsky AK
    Dis Mon; 2005; 51(2-3):112-5. PubMed ID: 15900262
    [No Abstract]   [Full Text] [Related]  

  • 35. [Control of heparin and oral anticoagulants, with micromethods: thrombin time, quick determination with addition of protamine].
    Seiler K; Müller G; Duckert F
    Schweiz Med Wochenschr; 1970 Sep; 100(36):1522-8. PubMed ID: 5524716
    [No Abstract]   [Full Text] [Related]  

  • 36. Control of heparin therapy. Sensitivity of the activated partial thromboplastin time for monitoring the antithrombotic effects of heparin.
    Zucker S; Cathey MH
    J Lab Clin Med; 1969 Feb; 73(2):320-6. PubMed ID: 5764028
    [No Abstract]   [Full Text] [Related]  

  • 37. Control of anticoagulant and antiplatelet therapy. Managing patients with acute thrombotic disorders.
    Anderson DR; Fernandez LA
    Can Fam Physician; 1993 Feb; 39():290-4, 297-300, 303-4. PubMed ID: 8495120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Importance of standardization in the biological monitoring of anti-vitamin K therapy].
    Forestier F; Boneu B; Potron G; Boisseau M; Coqueret B; Saffar S; Chambrette B
    Nouv Rev Fr Hematol (1978); 1986; 28(3):157-62. PubMed ID: 3748800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prescription and monitoring of antithrombotic treatment. First part: anticoagulants].
    Boneu B
    Rev Prat; 2004 Mar; 54(6):651-6. PubMed ID: 15222619
    [No Abstract]   [Full Text] [Related]  

  • 40. [Control of oral anticoagulant therapy using the Hepato-Quick-test].
    Heene DL
    Med Welt; 1974 Sep; 25(39):1529-31. PubMed ID: 4214975
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.